Amgen And Cytokinetics Announce Late-Breaking Presentation Of COSMIC-HF Trial At AHA Scientific Sessions 2015
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Cytokinetics (CYTK) and Amgen Inc. (AMGN) Announce COSMIC-HF Data; Roth Capital Raises Price Target to $22
November 9, 2015 7:32 AM ESTRoth Capital maintained a Buy rating on Cytokinetics (NASDAQ: CYTK), and raised the price target to $22.00 (from $18.00), following announced full data from COSMIC-HF at AHA. The large data set was announced jointly by Cytokinetics and global partner Amgen (NASDAQ:... More
Amgen (AMGN), Cytokinetics (CYTK) Announce COSMIC-HF Met Primary Endpoint
November 9, 2015 6:16 AM ESTAmgen (Nasdaq: AMGN) and Cytokinetics Incorporated (Nasdaq: CYTK) announced the presentation of data from the expansion phase of COSMIC-HF (Chronic Oral... More
